Akatinol memantine pills 10mg №30

Composition

Pharmacology

Akatinol Memantine has a modulating effect on the glutamatergic system, being a noncompetitive antagonist of NMDA receptors. It has a pathogenetic effect on degenerative processes in the central and peripheral nervous system. Regulates ion transport - blocks Calcium channels. It has a neuroprotective effect. Normalizes the membrane potential. Improves the transmission of nerve impulses. It improves cognitive processes, memory and learning ability, increases daily activity.

Indications and usage

Degenerative dementia (Alzheimer's type), vascular dementia, mixed dementia of all degrees of severity. Alzheimer's disease, Pick's disease
Dementia syndrome, depressive states with dementia
Weakening of memory, ability to concentrate and ability to learn
Diseases in which increased vigilance is required, for example, after head injuries, open or closed brain damage, coma,

Dosage and administration

 
Dosing regimen Akatinol memantine is set individually. It is recommended to begin treatment with the appointment of the minimum effective doses of Akatinol Memantine. 
Adults with dementia syndrome are prescribed during the 1st week of therapy at a dose of 5 mg per day, during the 2nd week at a dose of 10 mg per day. During the 3rd week - at a dose of 15-20 mg per day. If necessary, a further weekly dose increase of 10 mg is possible until a daily dose of 30 mg is reached. The optimal dose of Akatinol Memantine is achieved gradually, with an increase in dose every week.

Contraindications

 
Severe renal dysfunction; severe liver dysfunction; severe disorders of the central nervous system; pregnancy, breastfeeding, children under 18 years (due to lack of data). 
With caution Akatinol Memantine is prescribed to patients with thyrotoxicosis, epilepsy, convulsions (including a history), with myocardial infarction, heart failure.

Adverse reactions

Akatinol Memantine 
Dizziness, fatigue, anxiety, irritability, nausea.

Special notes

 
For patients with impaired renal function, the dosage regimen of Akatinol Memantine is set individually, depending on the clinical efficacy, under the control of renal function during treatment. 
When combined with the use of Akatinol, Memantine may change the effect of dantrolene or Baclofen, therefore, the doses of drugs should be selected individually.

Patients with Alzheimer's disease at the stage of moderate and severe dementia usually have impaired ability to drive vehicles or drive mechanisms.

Drug interactions

 
With simultaneous use of Acatinol memantine with L-dopa preparations, dopamine agonists, and anticholinergic agents, the action of the latter can be enhanced. With simultaneous use with barbiturates, neuroleptics, the effect of the latter may be reduced. When used together, change (increase or decrease) the effect of dantrolene or baclofen, so the doses of drugs should be selected individually. Concurrent administration with amantadine, ketamine and dexamethan should be avoided. There may be an increase in plasma levels of cimetidine, procainamide, quinidine, kinin and nicotine while taking it with memantine. It is possible to decrease the level of hydrochlorothiazide while taking Akatinol Memantine with memantine.

Storage conditions

Akatinol Memantine
At a temperature not higher than 25 C in places inaccessible for children.